Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (103) 103
Publication (21) 21
Patent (10) 10
Book Chapter (3) 3
Book Review (2) 2
Dissertation (2) 2
Newspaper Article (2) 2
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (53) 53
female (43) 43
index medicus (43) 43
male (43) 43
oncology (42) 42
middle aged (38) 38
aged (37) 37
adult (32) 32
cancer (25) 25
chemotherapy (23) 23
article (19) 19
antineoplastic combined chemotherapy protocols - therapeutic use (18) 18
aged, 80 and over (16) 16
care and treatment (15) 15
squamous cell carcinoma (15) 15
tumors (15) 15
hematology, oncology and palliative medicine (14) 14
patients (14) 14
carcinoma, squamous cell - drug therapy (13) 13
treatment outcome (13) 13
head (12) 12
head and neck neoplasms - drug therapy (12) 12
squamous-cell carcinoma (12) 12
disease-free survival (11) 11
head and neck cancer (11) 11
head and neck neoplasms - pathology (11) 11
paclitaxel (11) 11
radiotherapy (11) 11
neck (10) 10
radiation therapy (10) 10
antineoplastic combined chemotherapy protocols - adverse effects (9) 9
cetuximab (9) 9
cisplatin (9) 9
human necessities (9) 9
hygiene (9) 9
medical or veterinary science (9) 9
neoplasm staging (9) 9
pharmacology & pharmacy (9) 9
radiology (9) 9
radiology, nuclear medicine & medical imaging (9) 9
antineoplastic agents - therapeutic use (8) 8
carcinoma (8) 8
carcinoma, squamous cell - pathology (8) 8
carcinoma, squamous cell - therapy (8) 8
chemistry (8) 8
dose-response relationship, drug (8) 8
drug administration schedule (8) 8
electrotherapy (8) 8
head and neck neoplasms - therapy (8) 8
human-papillomavirus (8) 8
magnetotherapy (8) 8
metallurgy (8) 8
metastases (8) 8
organic chemistry (8) 8
peptides (8) 8
pharmacology/toxicology (8) 8
radiation (8) 8
retrospective studies (8) 8
surgery (8) 8
ultrasound therapy (8) 8
abridged index medicus (7) 7
dosage and administration (7) 7
maximum tolerated dose (7) 7
metastasis (7) 7
neck-cancer (7) 7
preparations for medical, dental, or toilet purposes (7) 7
radiology and nuclear medicine (7) 7
toxicity (7) 7
antimitotic agents (6) 6
antineoplastic agents (6) 6
bevacizumab (6) 6
cancer research (6) 6
carboplatin (6) 6
carcinoma, squamous cell - mortality (6) 6
carcinoma, squamous cell - secondary (6) 6
cisplatin - administration & dosage (6) 6
combination (6) 6
drug therapy (6) 6
everolimus (6) 6
lymphatic metastasis (6) 6
medicine & public health (6) 6
neoplasms - drug therapy (6) 6
nuclear radiation (6) 6
sirolimus - analogs & derivatives (6) 6
specific therapeutic activity of chemical compounds ormedicinal preparations (6) 6
squamous cell carcinoma of head and neck (6) 6
trial (6) 6
animals (5) 5
antibodies, monoclonal, humanized (5) 5
antineoplastic agents - administration & dosage (5) 5
antineoplastic agents - adverse effects (5) 5
carcinoma, squamous cell - metabolism (5) 5
chemoradiotherapy - methods (5) 5
head and neck neoplasms - mortality (5) 5
head and neck squamous cell carcinoma (5) 5
health aspects (5) 5
metastatic breast-cancer (5) 5
mice (5) 5
mtor (5) 5
neoplasm recurrence, local - drug therapy (5) 5
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (121) 121
French (3) 3
Chinese (1) 1
German (1) 1
Korean (1) 1
Portuguese (1) 1
Spanish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Systemic therapy in the management of metastatic or locally recurrent adenoid cystic carcinoma of the salivary glands: a systematic review
by Laurie, Scott A, Dr and Ho, Alan L, MD and Fury, Matthew G, MD and Sherman, Eric, MD and Pfister, David G, Prof
Lancet Oncology, The, ISSN 1470-2045, 2011, Volume 12, Issue 8, pp. 815 - 824
Summary Adenoid cystic carcinomas (ACC) are rare cancers usually arising in the salivary glands. Once metastatic, the natural history can vary; some patients... 
Hematology, Oncology and Palliative Medicine | PHASE-II TRIAL | ONCOLOGY-GROUP | MALIGNANT-TUMORS | PROGNOSTIC-FACTORS | ONCOLOGY | C-KIT | FOLLOW-UP | COOPERATIVE GROUP | CISPLATIN COMBINATION CHEMOTHERAPY | DISTANT METASTASES | IMATINIB MESYLATE | Recurrence | Carcinoma, Adenoid Cystic - drug therapy | Salivary Gland Neoplasms - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Humans | Carcinoma, Adenoid Cystic - secondary | Antineoplastic Agents - therapeutic use | Clinical Trials as Topic | Chemotherapy | Relapse | Analysis | Lung cancer | Metastasis | Cancer | Diseases
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma
by Migden, Michael R and Rischin, Danny and Schmults, Chrysalyne D and Guminski, Alexander and Hauschild, Axel and Lewis, Karl D and Chung, Christine H and Hernandez-Aya, Leonel and Lim, Annette M and Chang, Anne Lynn S and Rabinowits, Guilherme and Thai, Alesha A and Dunn, Lara A and Hughes, Brett G.M and Khushalani, Nikhil I and Modi, Badri and Schadendorf, Dirk and Gao, Bo and Seebach, Frank and Li, Siyu and Li, Jingjin and Mathias, Melissa and Booth, Jocelyn and Mohan, Kosalai and Stankevich, Elizabeth and Babiker, Hani M and Brana, Irene and Gil-Martin, Marta and Homsi, Jade and Johnson, Melissa L and Moreno, Victor and Niu, Jiaxin and Owonikoko, Taofeek K and Papadopoulos, Kyriakos P and Yancopoulos, George D and Lowy, Israel and Fury, Matthew G
The New England Journal of Medicine, ISSN 0028-4793, 07/2018, Volume 379, Issue 4, pp. 341 - 351
Among patients with advanced cutaneous squamous-cell carcinoma, the PD-1 inhibitor cemiplimab induced a response in approximately half the patients and was... 
MISMATCH-REPAIR DEFICIENCY | MEDICINE, GENERAL & INTERNAL | MANAGEMENT | NONMELANOMA SKIN-CANCER | SOLID TUMORS | LANDSCAPE | SENSITIVITY | CONSENSUS | TUMOR MUTATIONAL BURDEN | GUIDELINE | Skin Neoplasms - pathology | Skin Neoplasms - drug therapy | Carcinoma, Squamous Cell - pathology | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antibodies, Monoclonal - therapeutic use | Male | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Antineoplastic Agents - therapeutic use | Dose-Response Relationship, Drug | Disease-Free Survival | Carcinoma, Squamous Cell - drug therapy | Antineoplastic Agents - adverse effects | Immunotherapy | Aged, 80 and over | Adult | Carcinoma, Squamous Cell - secondary | Female | Aged | Programmed Cell Death 1 Receptor - immunology | Neoplasm Staging | Monoclonal antibodies | Squamous cell carcinoma | Dosage and administration | Safety and security measures | Drug therapy | Intravenous administration | PD-1 protein | Body weight | Oncology | Metastasis | Cancer therapies | Metastases | Surgery | Constipation | Drug dosages | Departments | Statistical analysis | Dermatology | Diarrhea | Fatigue | Nausea | Patients | Medicine | Studies | Immunosuppression | Hospitals | Immune checkpoint | Womens health | Response rates | Skin | Health risk assessment | Tumors
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text New chapter in our understanding of human papillomavirus-related head and neck cancer
by Pfister, David G and Fury, Matthew G
Journal of Clinical Oncology, ISSN 0732-183X, 10/2014, Volume 32, Issue 30, pp. 3349 - 3352
SURVIVAL | OROPHARYNGEAL | RISK-FACTOR | ONCOLOGY | RECURRENT | METASTASES | SQUAMOUS-CELL CARCINOMA | HPV-RELATED HEAD | TRENDS | CHEMOTHERAPY | Carcinoma, Squamous Cell - virology | Humans | Female | Male | Neoplasm Proteins - analysis | Oropharyngeal Neoplasms - virology | Papillomaviridae - isolation & purification | Cyclin-Dependent Kinase Inhibitor p16
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Intensity-Modulated Radiotherapy in the Treatment of Oropharyngeal Cancer: An Update of the Memorial Sloan-Kettering Cancer Center Experience
by Setton, Jeremy, B.A and Caria, Nicola, M.D and Romanyshyn, Jonathan, M.D and Koutcher, Lawrence, M.D and Wolden, Suzanne L., M.D and Zelefsky, Michael J., M.D and Rowan, Nicholas, B.A and Sherman, Eric J., M.D and Fury, Matthew G., M.D., Ph.D and Pfister, David G., M.D and Wong, Richard J., M.D and Shah, Jatin P., M.D and Kraus, Dennis H., M.D and Shi, Weiji, M.S and Zhang, Zhigang, Ph.D and Schupak, Karen D., M.D and Gelblum, Daphna Y., M.D and Rao, Shyam D., M.D., Ph.D and Lee, Nancy Y., M.D
International Journal of Radiation Oncology, Biology, Physics, ISSN 0360-3016, 2012, Volume 82, Issue 1, pp. 291 - 298
Purpose To update the Memorial Sloan-Kettering Cancer Center’s experience with intensity-modulated radiotherapy (IMRT) in the treatment of oropharyngeal cancer... 
Radiology | Hematology, Oncology and Palliative Medicine | Head-and-neck cancer | Dysphagia | IMRT | Xerostomia | Oropharyngeal cancer | HEAD | SPARING RADIOTHERAPY | NECK-CANCER | RADIATION-THERAPY | SALIVARY-GLAND FUNCTION | IMPACT | ONCOLOGY | SQUAMOUS-CELL CARCINOMA | QUALITY-OF-LIFE | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING | Pharyngeal Neoplasms - radiotherapy | Follow-Up Studies | Humans | Middle Aged | Oropharyngeal Neoplasms - mortality | Palate, Soft | Male | Oropharyngeal Neoplasms - pathology | Pharyngeal Neoplasms - drug therapy | Tongue Neoplasms - drug therapy | Incidence | New York City | Palatal Neoplasms - mortality | Treatment Failure | Aged, 80 and over | Adult | Female | Xerostomia - epidemiology | Tongue Neoplasms - radiotherapy | Radiotherapy Dosage | Tongue Neoplasms - mortality | Tonsillar Neoplasms - pathology | Oropharyngeal Neoplasms - drug therapy | Palatal Neoplasms - radiotherapy | Deglutition Disorders - epidemiology | Palatal Neoplasms - pathology | Oropharyngeal Neoplasms - radiotherapy | Cancer Care Facilities | Tonsillar Neoplasms - mortality | Tongue Neoplasms - pathology | Pharyngeal Neoplasms - mortality | Analysis of Variance | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Tonsillar Neoplasms - radiotherapy | Tonsillar Neoplasms - drug therapy | Pharyngeal Neoplasms - pathology | Aged | Palatal Neoplasms - drug therapy | Neoplasm Staging | Radiotherapy, Intensity-Modulated | Care and treatment | Throat cancer | Radiotherapy | Nuclear radiation | Cancer | PATIENTS | NEOPLASMS | FAILURES | METASTASES | PLATINUM | RADIATION DOSES | LYMPHATIC SYSTEM | CHEMOTHERAPY | PLANNING | PHARYNX | TONGUE | WOMEN | MEN | RADIOLOGY AND NUCLEAR MEDICINE | NECK | RADIOTHERAPY
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Treatment patterns and outcomes among patients with advanced cutaneous squamous cell carcinoma (CSCC) in a US community oncology setting
by Cowey, C. Lance and Robert, Nicholas J and Davies, Kalatu and Espirito, Janet L and Frytak, Jennifer R and Lowy, Israel and Fury, Matthew G
Journal of Clinical Oncology, ISSN 0732-183X, 05/2019, Volume 37, Issue 15_suppl, pp. e21033 - e21033
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Phase 2 study evaluating the combination of sorafenib and temsirolimus in the treatment of radioactive iodine‐refractory thyroid cancer
by Sherman, Eric J and Dunn, Lara A and Ho, Alan L and Baxi, Shrujal S and Ghossein, Ronald A and Fury, Matthew G and Haque, Sofia and Sima, Cami S and Cullen, Grace and Fagin, James A and Pfister, David G
Cancer, ISSN 0008-543X, 11/2017, Volume 123, Issue 21, pp. 4114 - 4121
BACKGROUND Patients with recurrent and/or metastatic, radioactive iodine‐refractory thyroid carcinoma have limited treatment options. Sorafenib, an oral kinase... 
anaplastic thyroid cancer | v‐Raf murine sarcoma viral oncogene homolog B (BRAF) mutation | thyroid cancer | sorafenib | mammalian target of rapamycin (mTOR) inhibition | v-Raf murine sarcoma viral oncogene homolog B (BRAF) mutation | BROAD-SPECTRUM | II TRIAL | MTOR | LENVATINIB | ONCOLOGY | HISTOLOGIC SUBTYPES | DOUBLE-BLIND | TARGETS | CARCINOMA | PROGRESSION | Niacinamide - analogs & derivatives | Adenocarcinoma, Follicular - radiotherapy | Adenocarcinoma, Follicular - pathology | Humans | Middle Aged | Radiation Tolerance | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Adenocarcinoma, Follicular - genetics | Male | Antineoplastic Agents - therapeutic use | Iodine Radioisotopes - therapeutic use | Antineoplastic Agents - adverse effects | Phenylurea Compounds - adverse effects | Adenocarcinoma, Follicular - drug therapy | Aged, 80 and over | Adult | Female | Sirolimus - adverse effects | Sirolimus - analogs & derivatives | Drug Administration Schedule | Niacinamide - adverse effects | Treatment Outcome | Thyroid Neoplasms - radiotherapy | Niacinamide - administration & dosage | Disease-Free Survival | Sirolimus - administration & dosage | Thyroid Neoplasms - genetics | Phenylurea Compounds - administration & dosage | Thyroid Neoplasms - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Aged | Mutation | Thyroid Neoplasms - pathology | Temsirolimus | Cancer patients | Care and treatment | Dosage and administration | Thyroid cancer | Drug therapy | TOR protein | Intravenous administration | Mucositis | Toxicity | Anemia | Cytotoxicity | Fatigue | Rapamycin | Metastasis | Cancer therapies | Patients | Metastases | Thyroid carcinoma | Hyperglycemia | Chemotherapy | Inhibitors | Quality | Response rates | Background radiation | Iodine | Cancer | Thyroid | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Reply to B. O'Sullivan et al
by Pfister, David G and Baxi, Shrujal S and Dunn, Lara A and Fury, Matthew G
Journal of Clinical Oncology, ISSN 0732-183X, 05/2015, Volume 33, Issue 15, pp. 1710 - 1710
Carcinoma, Squamous Cell - virology | Humans | Female | Male | Neoplasm Proteins - analysis | Oropharyngeal Neoplasms - virology | Papillomaviridae - isolation & purification
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Dynamic Contrast-Enhanced Magnetic Resonance Imaging as a Predictor of Outcome in Head-and-Neck Squamous Cell Carcinoma Patients With Nodal Metastases
by Shukla-Dave, Amita, Ph.D and Lee, Nancy Y., M.D and Jansen, Jacobus F.A., Ph.D and Thaler, Howard T., Ph.D and Stambuk, Hilda E., M.D and Fury, Matthew G., M.D and Patel, Snehal G., M.D and Moreira, Andre L., M.D and Sherman, Eric, M.D and Karimi, Sasan, M.D and Wang, Ya, M.S and Kraus, Dennis, M.D and Shah, Jatin P., M.D and Pfister, David G., M.D and Koutcher, Jason A., M.D., Ph.D
International Journal of Radiation Oncology, Biology, Physics, ISSN 0360-3016, 04/2012, Volume 82, Issue 5, pp. 1837 - 1844
Purpose Dynamic contrast-enhanced MRI (DCE-MRI) can provide information regarding tumor perfusion and permeability and has shown prognostic value in certain... 
Radiology | Hematology, Oncology and Palliative Medicine | Dynamic contrast enhanced MRI (DCE-MRI) | Volume transfer constant (Ktrans) | Head and neck squamous cell carcinoma (HNSCC) | Volume transfer constant (K-trans) | Volume transfer constant (K | FDG-PET | SURVIVAL | LARYNGEAL-CANCER | INTENSITY-MODULATED RADIOTHERAPY | BLOOD-VOLUME | CHEMOTHERAPY | BREAST | PROGNOSTIC-FACTOR | THERAPY | ONCOLOGY | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING | TUMOR VOLUME | Oropharyngeal Neoplasms - therapy | Follow-Up Studies | Carcinoma, Squamous Cell - pathology | Humans | Middle Aged | Oropharyngeal Neoplasms - mortality | Magnetic Resonance Imaging - methods | Male | Oropharyngeal Neoplasms - secondary | Oropharyngeal Neoplasms - pathology | Carcinoma, Squamous Cell - diagnosis | Mouth Neoplasms - diagnosis | Carcinoma, Squamous Cell - mortality | Statistics, Nonparametric | Aged, 80 and over | Adult | Female | Retrospective Studies | Oropharyngeal Neoplasms - diagnosis | Chemoradiotherapy - methods | Proportional Hazards Models | Carcinoma, Squamous Cell - therapy | Treatment Outcome | Lymphatic Metastasis | Mouth Neoplasms - mortality | Mouth Neoplasms - therapy | Disease-Free Survival | Contrast Media | Analysis of Variance | Mouth Neoplasms - pathology | Carcinoma, Squamous Cell - secondary | Aged | Mouth Neoplasms - secondary | Neoplasm Staging | Gadolinium DTPA | Squamous cell carcinoma | Carcinoma | Magnetic resonance imaging | Nuclear radiation | Patient outcomes | Radiation | Diagnostic imaging | Metastasis | Permeability | Cancer | Tumors | SURGERY | HEAD | PATIENTS | NMR IMAGING | PERMEABILITY | STATISTICS | METASTASES | CARCINOMAS | RADIOLOGY AND NUCLEAR MEDICINE | NECK | HAZARDS | Dynamic Contrast Enhanced-MRI (DCE-MRI) | volume transfer constant (Ktrans) | head and neck squamous cell carcinoma (HNSCC)
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text A Phase Ib Study of Cetuximab and BYL719 (Alpelisib) Concurrent with Intensity-Modulated Radiation Therapy in Stage III-IVB Head and Neck Squamous Cell Carcinoma
by Dunn, Lara A and Riaz, Nadeem and Fury, Matthew G and McBride, Sean M and Michel, Loren and Lee, Nancy Y and Sherman, Eric J and Baxi, Shrujal S and Haque, Sofia S and Katabi, Nora and Wong, Richard J and Xiao, Han and Ho, Alan L and Pfister, David G
International Journal of Radiation OncologyBiologyPhysics, ISSN 0360-3016, 10/2019
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text A phase 1 study of everolimus plus docetaxel plus cisplatin as induction chemotherapy for patients with locally and/or regionally advanced head and neck cancer
by Fury, Matthew G and Sherman, Eric and Ho, Alan L and Xiao, Han and Tsai, Frank and Nwankwo, Oby and Sima, Camelia and Heguy, Adrian and Katabi, Nora and Haque, Sofia and Pfister, David G
Cancer, ISSN 0008-543X, 05/2013, Volume 119, Issue 10, pp. 1823 - 1831
BACKGROUND: Activation of the phosphatidylinositol‐3‐kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway is common in head and neck cancers, and it... 
phase 1 | everolimus | squamous | induction | neck | MAMMALIAN TARGET | ADVANCED SOLID TUMORS | INHIBITOR EVEROLIMUS | COMBINATION | MTOR | PACLITAXEL | ONCOLOGY | UNRESECTABLE HEAD | METASTATIC BREAST-CANCER | RAPAMYCIN INHIBITOR | SQUAMOUS-CELL CANCER | Smoking - adverse effects | TOR Serine-Threonine Kinases - metabolism | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Phosphatidylinositol 3-Kinases - metabolism | Head and Neck Neoplasms - metabolism | Cisplatin - administration & dosage | Adult | Female | Proto-Oncogene Proteins c-akt - metabolism | Everolimus | Papillomavirus Infections - complications | Sirolimus - analogs & derivatives | Drug Administration Schedule | Risk Assessment | Risk Factors | Head and Neck Neoplasms - drug therapy | Induction Chemotherapy - methods | Treatment Outcome | Head and Neck Neoplasms - pathology | Induction Chemotherapy - adverse effects | Disease-Free Survival | Sirolimus - administration & dosage | Taxoids - administration & dosage | Maximum Tolerated Dose | Signal Transduction - drug effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Mutation | Neoplasm Staging | Head and neck cancer | Chemotherapy | Usage | Care and treatment | Drug therapy, Combination | Cancer | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Phase II Study Evaluating the Combination of Sorafenib and Temsirolimus in the Treatment of Radioactive Iodine-Refractory Thyroid Cancer
by Sherman, Eric J and Dunn, Lara and Ho, Alan L and Baxi, Shrujal and Ghossein, Ronald A and Fury, Matthew G and Haque, Sofia and Sima, Cami and Cullen, Grace and Fagin, James and Pfister, David G
Cancer, ISSN 0008-543X, 11/2017, Volume 123, Issue 21, pp. 4114 - 4121
mTOR inhibition | Thyroid Cancer | Sorafenib | Anaplastic Thyroid Cancer | BRAF mutation
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Phase I study of induction chemotherapy with afatinib, ribavirin, and weekly carboplatin and paclitaxel for stage IVA/IVB human papillomavirus‐associated oropharyngeal squamous cell cancer
by Dunn, Lara A and Fury, Matthew G and Sherman, Eric J and Ho, Alan A and Katabi, Nora and Haque, Sofia S and Pfister, David G
Head & Neck, ISSN 1043-3074, 02/2018, Volume 40, Issue 2, pp. 233 - 241
Background The human papillomavirus (HPV) E6 oncoprotein enhances the oncogenic potential of ErbB proteins in HPV‐related malignancies. This phase I study... 
afatinib | ribavirin | oropharyngeal cancer | human papillomavirus | squamous cell carcinoma | TRANSFORMATION | SURGERY | HEAD | BINDING MOTIF | PROTEIN | MESSENGER-RNA CAP | TYPE-16 | CERVICAL NEOPLASIA | NECK-CANCER | OTORHINOLARYNGOLOGY | EIF4E | CARCINOMA | Afatinib - administration & dosage | Oropharyngeal Neoplasms - drug therapy | Papillomavirus Infections - complications | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Carcinoma, Squamous Cell - virology | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Carboplatin - administration & dosage | Induction Chemotherapy | Male | Oropharyngeal Neoplasms - virology | Papillomaviridae - isolation & purification | Antiviral Agents - administration & dosage | Dose-Response Relationship, Drug | Carcinoma, Squamous Cell - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Progression-Free Survival | Ribavirin - administration & dosage | Papillomavirus Infections - drug therapy | Aged | Neoplasm Staging | Paclitaxel - administration & dosage | Papillomaviruses | Proteins | Chemotherapy | Squamous cell carcinoma | Paclitaxel | Papillomavirus infections | Ribavirin | Cancer | Human papillomavirus | Toxicity | ErbB protein | Carboplatin | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Responses of metastatic basal cell and cutaneous squamous cell carcinomas to anti-PD1 monoclonal antibody REGN2810
by Falchook, Gerald S and Leidner, Rom and Stankevich, Elizabeth and Piening, Brian and Bifulco, Carlo and Lowy, Israel and Fury, Matthew G
Journal for ImmunoTherapy of Cancer, ISSN 2051-1426, 11/2016, Volume 4, Issue 1, p. 70
Background: Basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (CSCC) share exposure to UV light as the dominant risk factor, and these tumors... 
Basal cell carcinoma | Cutaneous squamous cell carcinoma | Immune checkpoint inhibitor | Mutation burden | REGN2810 | Programmed Death-1 | Phase 1 | SKIN CANCERS | ONCOLOGY | PD-1 BLOCKADE | IMMUNOLOGY | Skin Neoplasms - pathology | Skin Neoplasms - drug therapy | Antibodies, Monoclonal - pharmacology | Carcinoma, Squamous Cell - metabolism | Humans | Middle Aged | Antibodies, Monoclonal - therapeutic use | Male | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Tomography, X-Ray Computed | Treatment Outcome | Carcinoma, Basal Cell - metabolism | Antineoplastic Agents, Immunological - pharmacology | Carcinoma, Basal Cell - diagnosis | Carcinoma, Squamous Cell - diagnosis | Neoplasm Metastasis | Carcinoma, Squamous Cell - drug therapy | Antineoplastic Agents, Immunological - therapeutic use | Skin Neoplasms - diagnosis | Carcinoma, Basal Cell - drug therapy | Female | Aged | Neoplasm Staging | Squamous cell carcinoma | Care and treatment | Monoclonal antibodies | Development and progression | Research | Health aspects | Risk factors | Consent | Funding | Mutation | Metastasis | Drug dosages | Patients | Manuscripts | Deoxyribonucleic acid--DNA | Pharmaceuticals | Tumors
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Full Text Treatment patterns and costs in cutaneous squamous cell carcinoma (CSCC) patients with nodal dissection, chemotherapy, and/or radiation therapy
by Ruiz, Emily S and Chen, Chieh-I and Deering, Katie and Xu, Yingxin and Kuznik, Andreas and Sasane, Medha and Ye, Fen and Harshaw, Qing and Andria, Michael L and Fury, Matthew G and Singh, Kanwarjit and Schmults, Chrysalyne
Journal of Clinical Oncology, ISSN 0732-183X, 05/2018, Volume 36, Issue 15_suppl, pp. e18703 - e18703
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
15. Full Text Phase Ib study of cetuximab + BYL719 + IMRT in stage III-IVB head and neck squamous cell carcinoma (HNSCC)
by Dunn, Lara and Riaz, Nadeem and Baxi, Shrujal S and McBride, Sean Matthew and Sherman, Eric Jeffrey and Michel, Loren and Haque, Sofia and Katabi, Nora and Wong, Richard J and Xiao, Han and Lee, Nancy Y and Fury, Matthew G and Ho, Alan Loh and Pfister, David G
Journal of Clinical Oncology, ISSN 0732-183X, 05/2017, Volume 35, Issue 15_suppl, pp. 6081 - 6081
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
16. Full Text TUMOR METABOLISM AND PERFUSION IN HEAD AND NECK SQUAMOUS CELL CARCINOMA: PRETREATMENT MULTIMODALITY IMAGING WITH H-1 MAGNETIC RESONANCE SPECTROSCOPY, DYNAMIC CONTRAST-ENHANCED MRI, AND [F-18]FDG-PET
by Jansen, Jacobus F. A and Schoder, Heiko and Lee, Nancy Y and Stambuk, Hilda. E and Wang, Ya and Fury, Matthew G and Patel, Snehal G and Pfister, David G and Shah, Jatin P and Koutcher, Jason A and Shukla-Dave, Amita
International Journal of Radiation Oncology Biology Physics, ISSN 0360-3016, 01/2012, Volume 82, Issue 1, pp. 299 - 307
Purpose: To correlate proton magnetic resonance spectroscopy (H-1-MRS), dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI), and F-18-labeled... 
Proton magnetic resonance spectroscopy | Dynamic contrast-enhanced MRI | Head and neck squamous cell carcinoma | Short-term treatment response | [F-18]FDG-PET | FDG-PET | PARAMETERS | PROGNOSTIC VALUE | CANCER | F-18-FDG PET | POSITRON-EMISSION-TOMOGRAPHY | ONCOLOGY | RADIATION TREATMENT | LYMPHOMA | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
17. Full Text A phase 2 study of bevacizumab with cisplatin plus intensity‐modulated radiation therapy for stage III/IVB head and neck squamous cell cancer
by Fury, Matthew G and Lee, Nancy Y and Sherman, Eric and Lisa, Donna and Kelly, Katherine and Lipson, Brynna and Carlson, Diane and Stambuk, Hilda and Haque, Sofia and Shen, Ronglai and Kraus, Dennis and Shah, Jatin and Pfister, David G
Cancer, ISSN 0008-543X, 10/2012, Volume 118, Issue 20, pp. 5008 - 5014
BACKGROUND: For patients with stage III through IVB head and neck squamous cell carcinoma (HNSCC), concurrent high‐dose cisplatin plus radiation therapy is a... 
bevacizumab | head and neck | phase 2 | cisplatin | radiation | HYDROXYUREA | HUMAN-PAPILLOMAVIRUS | II TRIAL | CHEMOTHERAPY | ONCOLOGY | RADIOTHERAPY | CARCINOMA | CONCURRENT CHEMORADIOTHERAPY | ENDOTHELIAL GROWTH-FACTOR | Humans | Middle Aged | Head and Neck Neoplasms - drug therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Combined Modality Therapy | Carcinoma, Squamous Cell - radiotherapy | Bevacizumab | Cisplatin - administration & dosage | Disease-Free Survival | Head and Neck Neoplasms - radiotherapy | Antibodies, Monoclonal, Humanized - administration & dosage | Carcinoma, Squamous Cell - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adult | Female | Aged | Radiotherapy, Intensity-Modulated | Dose-response relationship (Biochemistry) | Care and treatment | Usage | Patient outcomes | Head and neck cancer | Dosage and administration | Drug therapy | Radiotherapy | Cisplatin | Methods | Cancer | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
18. Full Text Noninvasive Assessment of Tumor Microenvironment Using Dynamic Contrast-Enhanced Magnetic Resonance Imaging and 18F-Fluoromisonidazole Positron Emission Tomography Imaging in Neck Nodal Metastases
by Jansen, Jacobus F.A and Schöder, Heiko and Lee, Nancy Y and Wang, Ya and Pfister, David G and Fury, Matthew G and Stambuk, Hilda E and Humm, John L and Koutcher, Jason A and Shukla-Dave, Amita
International Journal of Radiation Oncology, Biology, Physics, ISSN 0360-3016, 2010, Volume 77, Issue 5, pp. 1403 - 1410
To assess noninvasively the tumor microenvironment of neck nodal metastases in patients with head-and-neck cancer by investigating the relationship between... 
Dynamic contrast-enhanced-MRI (DCE-MRI) | Head-and-neck cancer | 18F-FMISO PET | 18F-FDG | Humans | Middle Aged | Male | Lymphatic Metastasis | Positron-Emission Tomography | Lymph Nodes | Head and Neck Neoplasms | Journal Article | Research Support, N.I.H., Extramural | Carcinoma, Squamous Cell | Cell Hypoxia | Magnetic Resonance Imaging | Misonidazole | Statistics, Nonparametric | Aged, 80 and over | Female | Aged | Retrospective Studies | Radiopharmaceuticals | F-FMISO PET | F-FDG | Cell Hypoxia - physiology | Lymph Nodes - pathology | Radiopharmaceuticals - pharmacokinetics | Carcinoma, Squamous Cell - metabolism | Carcinoma, Squamous Cell - pathology | Head and Neck Neoplasms - diagnostic imaging | Lymph Nodes - metabolism | Magnetic Resonance Imaging - methods | Carcinoma, Squamous Cell - diagnostic imaging | Misonidazole - pharmacokinetics | Misonidazole - analogs & derivatives | Positron-Emission Tomography - methods | Head and Neck Neoplasms - metabolism | Head and Neck Neoplasms - pathology | Lymph Nodes - diagnostic imaging
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights